Aseem Undvall Anand

Aseem Undvall Anand is a seasoned expert in the field of radiopharmaceuticals and digital imaging solutions, currently serving as the Head of Biomarkers at Lantheus since March 2023. In this role, Aseem leads partnerships focused on innovative radiopharmaceuticals for neurology and oncology while developing novel imaging biomarkers. Prior to this, Aseem held the position of Vice President at Progenics Pharmaceuticals, where Aseem spearheaded the adoption of AI-enhanced software as a medical device. Aseem's extensive experience includes serving as a Site Manager at Progenics and as a Product Manager at EXINI Diagnostics, specializing in automated Bone Scan Index. Aseem also contributed significantly to clinical research at Memorial Sloan Kettering Cancer Center, where Aseem led trials to validate key biomarkers. Aseem holds a PhD in Medicine from Lund University and has academic ties to Columbia University.